Actively Recruiting
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Led by China Medical University Hospital · Updated on 2025-01-23
20
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
Sponsors
C
China Medical University Hospital
Lead Sponsor
C
China Medical University, Taiwan
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
CONDITIONS
Official Title
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 20 to 70 years with pathologically confirmed advanced (stage III or IV) non-small cell lung cancer
- Positive diagnosis of EGFR mutations
- Histologically or cytologically confirmed locally advanced or metastatic adenocarcinoma subtype NSCLC after failure of first-line EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, afatinib, or osimertinib)
- Adequate liver, kidney, and bone marrow function
You will not qualify if you...
- Previous serious side effects from first-line EGFR tyrosine kinase inhibitor treatment
- Known hypertension or chronic liver and gastrointestinal diseases
- Known brain metastasis
- Female participants who are pregnant or breastfeeding
- Known diagnosis of negative nPKCδ expression by immunohistochemistry (IHC)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
China Medical University Hospital
Taichung, Taiwan
Actively Recruiting
Research Team
C
Chih-Yen Tu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here